Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 2—February 2010
Research

Cost-effectiveness of Pharmaceutical-based Pandemic Influenza Mitigation Strategies1

Anthony T. NewallComments to Author , James G. Wood, Noemie Oudin, and C. Raina MacIntyre
Author affiliations: University of New South Wales, Sydney, New South Wales, Australia (A.T. Newall, J.G. Wood, C.R. MacIntyre); National Institute for Applied Sciences, Lyon, France (N. Oudin)

Main Article

Figure 3

Cost-effectiveness acceptability curves. Panels A and B show the healthcare system perspective; C and D show the societal perspective. In B and D, we assumed that half of the time (Q = 50%) the emergent pandemic strain would be would be of a subtype to which the stockpiled vaccine offered no protection. We did not explore the use of such a vaccine in subsequent pandemics. Costs and life-years discounted at 5% annually. A$, Australian dollars; LYS, life-year saved.

Figure 3. Cost-effectiveness acceptability curves. Panels A and B show the healthcare system perspective; C and D show the societal perspective. In B and D, we assumed that half of the time (Q = 50%) the emergent pandemic strain would be would be of a subtype to which the stockpiled vaccine offered no protection. We did not explore the use of such a vaccine in subsequent pandemics. Costs and life-years discounted at 5% annually. A$, Australian dollars; LYS, life-year saved.

Main Article

1This material was compiled before the declaration of pandemic (H1N1) 2009 and concerns stockpiling for a future influenza pandemic.

Page created: December 10, 2010
Page updated: December 10, 2010
Page reviewed: December 10, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external